Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 657.80

+1.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Felix B who wrote (3191)	12/21/2020 5:33:19 PM
From: CuttingEdge Bio	Read Replies (1) of 3557

They used PRN dosing with bispecific to demonstrate that pidgeon holing Eylea patients to label dose only, in comparison to PRN in the bispec arm, resulted in non-inferior result, with X% in PRN capable of treatment every 8 months, Y% every 12 months, Z% every 16 months etc. So the assumption being that none of the Eylea on PRN dosing could have lasted that long (which is not a valid assumption, there would be some percentage in each cateogry on mono too). But head to head PRN in both arms, maybe it would have been longer duration on the bispec arm, since Z% is considerable. (If only a trial was run to demonstrate this clearly!). In that scenario and looking at the phase 2 results, I suspect that head to head eylea+Ang2 PRN vs. eylea PRN also would be longer duration or higher Y% and Z% vs. mono too. So if they could develop that they could match this easily. (If there was a true advantage). But it seems they are forbidden to develop it further?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next